JP2019163290A5 - - Google Patents
Info
- Publication number
- JP2019163290A5 JP2019163290A5 JP2019090711A JP2019090711A JP2019163290A5 JP 2019163290 A5 JP2019163290 A5 JP 2019163290A5 JP 2019090711 A JP2019090711 A JP 2019090711A JP 2019090711 A JP2019090711 A JP 2019090711A JP 2019163290 A5 JP2019163290 A5 JP 2019163290A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- disease
- cancer
- unsubstituted
- independently
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 150000001875 compounds Chemical class 0.000 claims 11
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000009127 Glutaminase Human genes 0.000 claims 4
- 108010073324 Glutaminase Proteins 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 206010061218 Inflammation Diseases 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000004054 inflammatory process Effects 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010047115 Vasculitis Diseases 0.000 claims 2
- 239000000730 antalgic agent Substances 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000000739 antihistaminic agent Substances 0.000 claims 2
- 210000004027 cell Anatomy 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 239000003018 immunosuppressive agent Substances 0.000 claims 2
- 229940125721 immunosuppressive agent Drugs 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 206010025135 lupus erythematosus Diseases 0.000 claims 2
- -1 nitro, amino Chemical group 0.000 claims 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 150000003431 steroids Chemical class 0.000 claims 2
- 208000030507 AIDS Diseases 0.000 claims 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 1
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000003343 Antiphospholipid Syndrome Diseases 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000030767 Autoimmune encephalitis Diseases 0.000 claims 1
- 208000015338 Autoimmune hepatitis type 1 Diseases 0.000 claims 1
- 206010050245 Autoimmune thrombocytopenia Diseases 0.000 claims 1
- 208000003950 B-cell lymphoma Diseases 0.000 claims 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 208000009137 Behcet syndrome Diseases 0.000 claims 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000006386 Bone Resorption Diseases 0.000 claims 1
- 208000020084 Bone disease Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 206010014612 Encephalitis viral Diseases 0.000 claims 1
- 208000010334 End Stage Liver Disease Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 201000008808 Fibrosarcoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 208000032612 Glial tumor Diseases 0.000 claims 1
- 206010018338 Glioma Diseases 0.000 claims 1
- 206010018364 Glomerulonephritis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000015023 Graves' disease Diseases 0.000 claims 1
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 1
- 208000003923 Hereditary Corneal Dystrophies Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000017604 Hodgkin disease Diseases 0.000 claims 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010024229 Leprosy Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 241000243985 Onchocerca volvulus Species 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000011152 Pemphigus Diseases 0.000 claims 1
- 208000031845 Pernicious anaemia Diseases 0.000 claims 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 206010058141 Skin graft rejection Diseases 0.000 claims 1
- 206010041067 Small cell lung cancer Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010042742 Sympathetic ophthalmia Diseases 0.000 claims 1
- 206010042971 T-cell lymphoma Diseases 0.000 claims 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 206010047642 Vitiligo Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001919 adrenal effect Effects 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000000735 allogeneic effect Effects 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 230000001387 anti-histamine Effects 0.000 claims 1
- 229940125715 antihistaminic agent Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 1
- 201000004982 autoimmune uveitis Diseases 0.000 claims 1
- 230000024279 bone resorption Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000029028 brain injury Diseases 0.000 claims 1
- 230000003197 catalytic effect Effects 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000011444 chronic liver failure Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 206010011005 corneal dystrophy Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000002491 encephalomyelitis Diseases 0.000 claims 1
- 206010014801 endophthalmitis Diseases 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000007565 gingivitis Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000009326 ileitis Diseases 0.000 claims 1
- 210000000987 immune system Anatomy 0.000 claims 1
- 201000001371 inclusion conjunctivitis Diseases 0.000 claims 1
- 208000013256 infectious meningitis Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 239000010985 leather Substances 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 206010028417 myasthenia gravis Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 208000009928 nephrosis Diseases 0.000 claims 1
- 231100001027 nephrosis Toxicity 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000002042 onchocerciasis Diseases 0.000 claims 1
- 210000000056 organ Anatomy 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229940127084 other anti-cancer agent Drugs 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 210000004116 schwann cell Anatomy 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 206010044325 trachoma Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 201000002498 viral encephalitis Diseases 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- BGVTUIRPHLSMJU-UHFFFAOYSA-N Cc1nnc(C)cc1 Chemical compound Cc1nnc(C)cc1 BGVTUIRPHLSMJU-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN36/CHE/2014 | 2014-01-06 | ||
| IN39/CHE/2014 | 2014-01-06 | ||
| IN36CH2014 | 2014-01-06 | ||
| IN39CH2014 | 2014-01-06 | ||
| IN2647CH2014 | 2014-05-29 | ||
| IN2647/CHE/2014 | 2014-05-29 | ||
| IN2639/CHE/2014 | 2014-05-29 | ||
| IN2639CH2014 | 2014-05-29 | ||
| IN2783CH2014 | 2014-06-06 | ||
| IN2783/CHE/2014 | 2014-06-06 | ||
| IN3525CH2014 | 2014-07-18 | ||
| IN3525/CHE/2014 | 2014-07-18 | ||
| IN3612CH2014 | 2014-07-24 | ||
| IN3613/CHE/2014 | 2014-07-24 | ||
| IN3613CH2014 | 2014-07-24 | ||
| IN3612/CHE/2014 | 2014-07-24 | ||
| IN5438/CHE/2014 | 2014-10-31 | ||
| IN5438CH2014 | 2014-10-31 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562078A Division JP6783663B2 (ja) | 2014-01-06 | 2015-01-05 | 新規グルタミナーゼ阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019163290A JP2019163290A (ja) | 2019-09-26 |
| JP2019163290A5 true JP2019163290A5 (enExample) | 2019-11-07 |
Family
ID=52478027
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562079A Expired - Fee Related JP6666263B2 (ja) | 2014-01-06 | 2015-01-05 | グルタミナーゼの新規阻害剤 |
| JP2016562078A Expired - Fee Related JP6783663B2 (ja) | 2014-01-06 | 2015-01-05 | 新規グルタミナーゼ阻害剤 |
| JP2019090711A Pending JP2019163290A (ja) | 2014-01-06 | 2019-05-13 | 新規グルタミナーゼ阻害剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016562079A Expired - Fee Related JP6666263B2 (ja) | 2014-01-06 | 2015-01-05 | グルタミナーゼの新規阻害剤 |
| JP2016562078A Expired - Fee Related JP6783663B2 (ja) | 2014-01-06 | 2015-01-05 | 新規グルタミナーゼ阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US20160297761A1 (enExample) |
| EP (2) | EP3092236B1 (enExample) |
| JP (3) | JP6666263B2 (enExample) |
| KR (3) | KR20220013017A (enExample) |
| CN (5) | CN111892589A (enExample) |
| AU (1) | AU2015204210B2 (enExample) |
| BR (1) | BR112016015706A8 (enExample) |
| CA (2) | CA2934702A1 (enExample) |
| CL (1) | CL2016001715A1 (enExample) |
| DK (1) | DK3092236T3 (enExample) |
| EA (3) | EA033163B1 (enExample) |
| ES (1) | ES2833576T3 (enExample) |
| IL (1) | IL246362B (enExample) |
| SG (1) | SG11201605478XA (enExample) |
| WO (2) | WO2015101958A2 (enExample) |
| ZA (1) | ZA201604272B (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201504022RA (en) | 2012-11-21 | 2015-06-29 | Agios Pharmaceuticals Inc | Glutamase inhibitors and method of use |
| WO2014079011A1 (en) | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| CN111892589A (zh) * | 2014-01-06 | 2020-11-06 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
| AU2015231053B2 (en) * | 2014-03-21 | 2019-04-11 | Les Laboratoires Servier | Compounds and their methods of use |
| CR20160497A (es) * | 2014-04-30 | 2016-12-20 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
| SI3164394T1 (sl) | 2014-07-03 | 2020-08-31 | Board Of Regents, The University Of Texas System | GLS1 inhibitorji za zdravljenje bolezni |
| WO2016007647A1 (en) | 2014-07-09 | 2016-01-14 | The Johns Hopkins University | Glutaminase inhibitor discovery and nanoparticle-enhanced delivery for cancer therapy |
| WO2017004359A1 (en) * | 2015-06-30 | 2017-01-05 | Board Of Regents, University Of Texas System | Gls1 inhibitors for treating disease |
| CN108348492B (zh) * | 2015-07-31 | 2021-09-28 | 约翰霍普金斯大学 | 使用谷氨酰胺类似物的用于癌症和免疫疗法的方法 |
| US10842763B2 (en) | 2015-07-31 | 2020-11-24 | The Johns Hopkins University | Methods for cancer and immunotherapy using prodrugs of glutamine analogs |
| CN112920092B (zh) | 2015-07-31 | 2024-04-26 | 约翰霍普金斯大学 | 谷氨酰胺类似物的前药 |
| WO2017021177A1 (en) * | 2015-08-04 | 2017-02-09 | Universitat De Barcelona | Pharmaceutical combinations for use in the treatment of cancer |
| GB201520959D0 (en) * | 2015-11-27 | 2016-01-13 | Astrazeneca Ab And Cancer Res Technology Ltd | Bis-pyridazine compounds and their use in treating cancer |
| TW201733587A (zh) * | 2015-11-30 | 2017-10-01 | 阿斯特捷利康公司 | 1,3,4-噻二唑化合物及其在治療癌症中之用途 |
| TW201731511A (zh) | 2015-11-30 | 2017-09-16 | 阿斯特捷利康公司 | １，３，４-噻二唑化合物及其在治療癌症中之用途 |
| US9938265B2 (en) * | 2015-11-30 | 2018-04-10 | Astrazeneca Ab | 1,3,4-thiadiazole compounds and their use in treating cancer |
| US10246449B2 (en) | 2015-12-21 | 2019-04-02 | Council Of Scientific & Industrial Research | 1,2,3 triazole-thiazole compounds, process for preparation and use thereof |
| CN108602782B (zh) * | 2015-12-22 | 2022-06-17 | 德克萨斯大学系统董事会 | N-甲基-1h-1,2,3-三唑-4-甲酰胺化合物的盐形式和多晶型物 |
| CN107474024B (zh) * | 2016-06-08 | 2022-12-13 | 北京赛林泰医药技术有限公司 | 一种谷氨酰酶抑制剂及其组合物和用途 |
| WO2018102715A1 (en) * | 2016-12-02 | 2018-06-07 | Indiana University Research And Technology Corporation | Compositions and methods for treating and/or reducing corneal dystrophy |
| CN118108677A (zh) * | 2017-01-27 | 2024-05-31 | 康奈尔大学 | 两性离子修饰的聚合物和水凝胶 |
| ES2903182T3 (es) * | 2017-06-13 | 2022-03-31 | Medshine Discovery Inc | Compuesto como inhibidor GLS1 |
| CN111225903B (zh) | 2017-10-18 | 2024-08-16 | 德州大学系统董事会 | 谷氨酰胺酶抑制剂疗法 |
| MX387232B (es) | 2017-10-27 | 2025-03-18 | Boehringer Ingelheim Int | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. |
| US20190269705A1 (en) * | 2017-11-27 | 2019-09-05 | Regents Of The University Of Minnesota | Methods and materials for treating graft versus host disease |
| CA3108158C (en) * | 2018-07-31 | 2023-05-16 | Eli Lilly And Company | 5-methyl-4-fluoro-thiazol-2-yl compounds |
| KR20210060513A (ko) | 2018-09-19 | 2021-05-26 | 바이오젠 엠에이 인코포레이티드 | O-당단백질-2-아세트아미도-2-데옥시-3-d-글루코피라노시다제 억제제 |
| US20220119768A1 (en) * | 2018-11-08 | 2022-04-21 | The University Of Tokyo | Method for removing senescent cell, and method for preparing senescent cell |
| CN109223778B (zh) * | 2018-11-16 | 2021-07-27 | 上海市肺科医院 | C24h24n6o2s3在制备抗结核菌药物中的用途 |
| CA3121202A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| US11958818B2 (en) | 2019-05-01 | 2024-04-16 | Boehringer Ingelheim International Gmbh | (R)-(2-methyloxiran-2-yl)methyl 4-bromobenzenesulfonate |
| CN110746416A (zh) * | 2019-09-05 | 2020-02-04 | 中国药科大学 | 含有三氮唑结构的谷氨酰胺酶gls1抑制剂或其可药用的盐、其制备方法及用途 |
| EP4085056A1 (en) | 2020-01-03 | 2022-11-09 | Berg LLC | Polycyclic amides as ube2k modulators for treating cancer |
| CN111643669A (zh) * | 2020-06-30 | 2020-09-11 | 广东省中医院（广州中医药大学第二附属医院、广州中医药大学第二临床医学院、广东省中医药科学院） | 谷氨酰胺酶抑制剂在制备治疗银屑病的药物中的应用 |
| US12059408B2 (en) | 2020-08-13 | 2024-08-13 | Boehringer Ingelheim International Gmbh | Treatment of cognitive impairment associated with schizophrenia |
| WO2022078927A1 (en) | 2020-10-13 | 2022-04-21 | Boehringer Ingelheim International Gmbh | Process of reworking |
| JP2023545588A (ja) * | 2020-10-16 | 2023-10-30 | ツェーエムエム－フォルシュングスツェントルム フュア モレクラレ メディツィン ゲーエムベーハー | ヘテロ環式カリンｒｉｎｇユビキチンリガーゼ化合物及びその使用 |
| AU2022291768A1 (en) | 2021-06-16 | 2023-11-30 | Celgene Corporation | Azetidinyl compounds comprising a carboxylic acid group for the treatment of neurodegenerative diseases |
| CN114805346A (zh) * | 2021-07-08 | 2022-07-29 | 成都硕德药业有限公司 | 杂环类衍生物、其制备方法及用途 |
| CN116023375A (zh) * | 2021-10-25 | 2023-04-28 | 成都苑东生物制药股份有限公司 | 一种杂环类衍生物、其制备方法及用途 |
| TW202339719A (zh) | 2021-12-14 | 2023-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 用於治療慢性腎臟病之醛固酮合成酶抑制劑 |
| US20250288577A1 (en) * | 2022-04-29 | 2025-09-18 | Cornell University | Methods of treating a virus infection and methods of inhibiting viral replication |
| CN114874186B (zh) * | 2022-05-16 | 2023-07-11 | 深圳大学 | 一种谷氨酰胺酰基环化酶同工酶抑制剂及其制备方法与应用 |
| WO2024233839A1 (en) * | 2023-05-10 | 2024-11-14 | Leal Therapeutics, Inc. | Small molecule inhibitors of glutaminase |
| WO2025082274A1 (zh) * | 2023-10-17 | 2025-04-24 | 楚浦创制（武汉）医药科技有限公司 | 硫代羰基化合物及其应用 |
| CN119192178B (zh) * | 2024-09-23 | 2025-08-05 | 浙江师范大学行知学院 | 一种氨基脲衍生物及其制备方法与应用 |
| CN119656315B (zh) * | 2024-12-23 | 2025-10-17 | 重庆医科大学 | Gls1抑制剂在缓解溃疡性结肠炎中的应用 |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2104783A1 (en) * | 1970-07-14 | 1972-04-21 | Berlin Chemie Veb | 2,5-disubstd 2-amino-1,3,4-thiadiazoles-from 4-substd 1-acylthiosemic - virustatics |
| JPH0358980A (ja) * | 1989-07-28 | 1991-03-14 | Canon Inc | 液晶性化合物、これを含む液晶組成物、およびこれを使用した液晶素子 |
| EP0656210A1 (en) | 1993-11-19 | 1995-06-07 | Takeda Chemical Industries, Ltd. | Imidazole derivatives as glutaminose inhibitors |
| US6310093B1 (en) | 1997-08-29 | 2001-10-30 | Elan Pharmaceuticals, Inc. | Method of preventing neuronal death |
| CA2368230A1 (en) | 1999-04-02 | 2000-10-12 | Children's Hospital Los Angeles | Use of asparaginase and glutaminase to treat autoimmune disease and graft versus host disease |
| US6451828B1 (en) | 2000-08-10 | 2002-09-17 | Elan Pharmaceuticals, Inc. | Selective inhibition of glutaminase by bis-thiadiazoles |
| NO315152B1 (no) | 2001-06-28 | 2003-07-21 | Tomm Slater | Anordning for rensing av luft |
| WO2003022261A1 (en) | 2001-09-13 | 2003-03-20 | Miller Kenneth E | Method of alleviating pain |
| SE0300456D0 (sv) * | 2003-02-19 | 2003-02-19 | Astrazeneca Ab | Novel compounds |
| EP1597256A1 (en) * | 2003-02-21 | 2005-11-23 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| DE10326821A1 (de) | 2003-06-11 | 2005-01-05 | Medical Enzymes Ag | Pharmazeutische Kombinationspräparate zur Krebstherapie |
| WO2007001395A2 (en) | 2004-10-04 | 2007-01-04 | University Of South Carolina | Prevention and treatment of influenza with glutamine antagonist agents |
| JP4871290B2 (ja) | 2005-10-06 | 2012-02-08 | 日本曹達株式会社 | 架橋環状アミン化合物および有害生物防除剤 |
| US8465736B2 (en) | 2006-05-10 | 2013-06-18 | New Medical Enzymes Ag | Glutadon |
| TW200819437A (en) * | 2006-08-17 | 2008-05-01 | Astrazeneca Ab | Chemical compounds |
| US7638541B2 (en) * | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CL2007003841A1 (es) * | 2006-12-28 | 2008-03-14 | Metabolex Inc | Compuestos derivados de 4(5h-1 lambda-tiazol-2-il)piperidina; composicion farmaceutica que contiene a dichos compuestos; y su uso para tratar diabetes. |
| CN101754962B (zh) * | 2007-07-19 | 2013-12-25 | 赛马拜制药公司 | 作为rup3或gpr119受体的激动剂治疗糖尿病和代谢性病症的n-氮杂环状经取代吡咯、吡唑、咪唑、三唑和四唑衍生物 |
| CA2720950A1 (en) * | 2008-04-07 | 2009-10-15 | Irm Llc | Compounds and compositions as modulators of gpr119 activity |
| CA2722028C (en) | 2008-04-22 | 2013-09-24 | Daiichi Sankyo Company, Limited | 5-hydroxypyrimidine-4-carboxamide compound |
| US20100041663A1 (en) * | 2008-07-18 | 2010-02-18 | Novartis Ag | Organic Compounds as Smo Inhibitors |
| JPWO2010013849A1 (ja) * | 2008-08-01 | 2012-01-12 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| WO2010033871A2 (en) | 2008-09-18 | 2010-03-25 | The Johns Hopkins University | Compositions and methods targeting glutaminase |
| JP2012505898A (ja) * | 2008-10-16 | 2012-03-08 | シェーリング コーポレイション | ピロリジン、ピペリジンおよびピペラジン誘導体ならびにそれらの使用方法 |
| WO2010048149A2 (en) * | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| JP2010138082A (ja) * | 2008-12-09 | 2010-06-24 | Nippon Soda Co Ltd | 環状アミン化合物またはその塩、並びに有害生物防除剤 |
| WO2010111504A2 (en) | 2009-03-25 | 2010-09-30 | Cornell University | Inhibition of glutaminase c |
| JPWO2011025006A1 (ja) * | 2009-08-31 | 2013-01-31 | 日本ケミファ株式会社 | Ｇｐｒ１１９作動薬 |
| EP3444242A3 (en) * | 2009-11-05 | 2019-03-20 | Rhizen Pharmaceuticals S.A. | Novel benzopyran kinase modulators |
| ES2362770B1 (es) | 2009-12-24 | 2012-05-22 | Universidad De Sevilla | Uso de compuesto n-fenil-n'-(3-metil-2-butenil)tiourea para la elaboración de medicamentos destinados al tratamiento de la encefalopatía hepática. |
| CN102971304A (zh) | 2010-02-01 | 2013-03-13 | 日本化学医药株式会社 | Gpr119激动剂 |
| WO2011143160A2 (en) | 2010-05-10 | 2011-11-17 | The Johns Hopkins University | Metabolic inhibitor against tumors having an idh mutation |
| EP2571878B1 (en) * | 2010-05-17 | 2018-10-17 | Incozen Therapeutics Pvt. Ltd. | Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued -3h-[1,2,3]triazolo[4,5-b]pyridine compounds as modulators of protein kinases |
| US10064885B2 (en) | 2010-07-09 | 2018-09-04 | Massachusetts Institute Of Technology | Metabolic gene, enzyme, and flux targets for cancer therapy |
| US20130252983A1 (en) | 2010-09-10 | 2013-09-26 | Cornell University | Activating phosphorylation site on glutaminase c |
| JP2014094886A (ja) * | 2011-02-28 | 2014-05-22 | Nippon Chemiphar Co Ltd | Ｇｐｒ１１９作動薬 |
| CN103030597B (zh) | 2011-09-30 | 2014-10-01 | 南昌滨西科技有限公司 | 肾脏型谷氨酰胺酶抑制剂及其制备方法和用途 |
| AR088256A1 (es) | 2011-10-08 | 2014-05-21 | Novartis Ag | Derivados de carbamato / urea como antagonistas del receptor h3 |
| ES2761866T3 (es) * | 2011-11-21 | 2020-05-21 | Calithera Biosciences Inc | Inhibidores heterocíclicos de glutaminasa |
| US8604016B2 (en) | 2011-11-21 | 2013-12-10 | Calithera Biosciences Inc. | Heterocyclic inhibitors of glutaminase |
| US9618514B2 (en) | 2012-09-17 | 2017-04-11 | Agios Pharmaceuticals, Inc | Methods of evaluating patients using E-cadherin and vimentin |
| ES2899461T3 (es) | 2012-11-16 | 2022-03-11 | Calithera Biosciences Inc | Inhibidores heterocíclicos de glutaminasa |
| SG11201504022RA (en) | 2012-11-21 | 2015-06-29 | Agios Pharmaceuticals Inc | Glutamase inhibitors and method of use |
| WO2014079011A1 (en) * | 2012-11-22 | 2014-05-30 | Agios Pharmaceuticals, Inc. | Heterocyclic compounds for inhibiting glutaminase and their methods of use |
| US9029531B2 (en) | 2012-11-22 | 2015-05-12 | Agios Pharmaceuticals, Inc. | Compounds and their methods of use |
| CN105283182A (zh) | 2012-12-03 | 2016-01-27 | 卡利泰拉生物科技公司 | 用谷氨酰胺酶的杂环抑制剂治疗癌症 |
| CN111892589A (zh) * | 2014-01-06 | 2020-11-06 | 理森制药股份公司 | 谷氨酰胺酶抑制剂 |
| CR20160497A (es) * | 2014-04-30 | 2016-12-20 | Pfizer | Derivados de diheterociclo enlazado a cicloalquilo |
-
2015
- 2015-01-05 CN CN202010671865.6A patent/CN111892589A/zh active Pending
- 2015-01-05 JP JP2016562079A patent/JP6666263B2/ja not_active Expired - Fee Related
- 2015-01-05 CN CN202110114920.6A patent/CN112920180A/zh active Pending
- 2015-01-05 SG SG11201605478XA patent/SG11201605478XA/en unknown
- 2015-01-05 US US14/769,365 patent/US20160297761A1/en not_active Abandoned
- 2015-01-05 ES ES15705845T patent/ES2833576T3/es active Active
- 2015-01-05 CN CN201580006698.0A patent/CN105960405B/zh not_active Expired - Fee Related
- 2015-01-05 BR BR112016015706A patent/BR112016015706A8/pt not_active Application Discontinuation
- 2015-01-05 KR KR1020227001963A patent/KR20220013017A/ko not_active Ceased
- 2015-01-05 EA EA201691135A patent/EA033163B1/ru unknown
- 2015-01-05 JP JP2016562078A patent/JP6783663B2/ja not_active Expired - Fee Related
- 2015-01-05 EA EA201691134A patent/EA035499B1/ru unknown
- 2015-01-05 US US14/769,331 patent/US9783533B2/en not_active Expired - Fee Related
- 2015-01-05 WO PCT/IB2015/050076 patent/WO2015101958A2/en not_active Ceased
- 2015-01-05 EA EA201991183A patent/EA201991183A1/ru unknown
- 2015-01-05 CA CA2934702A patent/CA2934702A1/en not_active Abandoned
- 2015-01-05 KR KR1020167021582A patent/KR20160100408A/ko not_active Ceased
- 2015-01-05 EP EP15705845.4A patent/EP3092236B1/en not_active Not-in-force
- 2015-01-05 CA CA2934700A patent/CA2934700A1/en not_active Abandoned
- 2015-01-05 CN CN201580009614.9A patent/CN106029659B/zh not_active Expired - Fee Related
- 2015-01-05 WO PCT/IB2015/050075 patent/WO2015101957A2/en not_active Ceased
- 2015-01-05 DK DK15705845.4T patent/DK3092236T3/da active
- 2015-01-05 EP EP15705095.6A patent/EP3092235A2/en not_active Withdrawn
- 2015-01-05 AU AU2015204210A patent/AU2015204210B2/en not_active Ceased
- 2015-01-05 CN CN202010256915.4A patent/CN111393431A/zh active Pending
- 2015-01-05 KR KR1020167021580A patent/KR20160100407A/ko not_active Ceased
-
2016
- 2016-06-21 IL IL246362A patent/IL246362B/en unknown
- 2016-06-23 ZA ZA2016/04272A patent/ZA201604272B/en unknown
- 2016-07-05 CL CL2016001715A patent/CL2016001715A1/es unknown
-
2017
- 2017-08-31 US US15/693,291 patent/US10611759B2/en not_active Expired - Fee Related
-
2019
- 2019-05-13 JP JP2019090711A patent/JP2019163290A/ja active Pending
-
2020
- 2020-03-20 US US16/825,755 patent/US20210032236A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019163290A5 (enExample) | ||
| JP2017505808A5 (enExample) | ||
| JP2017501234A5 (enExample) | ||
| US20240174692A1 (en) | Pyrimidine aromatic ring compounds | |
| JP2020537657A5 (enExample) | ||
| JP7629580B1 (ja) | ベンゾピリミジン化合物及びその使用 | |
| JP2024166311A (ja) | 化合物、組成物、及び、方法 | |
| JP2010509342A5 (enExample) | ||
| JP2017516785A5 (enExample) | ||
| JP2020528889A5 (enExample) | ||
| HRP20211151T1 (hr) | Kristalinska tosilatna sol pi3k delta selektivnog inhibitora za uporabu u farmaceutskim formulacijama | |
| WO2023179629A1 (zh) | 取代桥环类抑制剂及其制备方法和应用 | |
| CA2669695A1 (en) | Tetrahydropyridinyl compounds for inflammation and immune-related uses | |
| JP2005534684A5 (enExample) | ||
| KR102658095B1 (ko) | 안드로겐 수용체 길항제로서 다이아릴티오하이단토인 화합물 | |
| WO2020167994A1 (en) | Compounds, compositions and methods | |
| CN105555768A (zh) | RORγ调节剂 | |
| AU2022412827A1 (en) | Heterocyclic compound having anti-tumor activity and use thereof | |
| JP2018502083A5 (enExample) | ||
| WO2022094400A1 (en) | Bicyclic compounds and uses thereof for the treatment of diseases | |
| JPWO2020086732A5 (enExample) | ||
| US20040138195A1 (en) | Anti-cancer 2,3-dihydro-1h-pyrrolo[3,2-f[quinoline complexes of cobalt and chromium | |
| JP7209723B2 (ja) | 肝臓送達に基づくゲムシタビンプロドラッグであるヌクレオシドの環状リン酸エステル化合物および応用 | |
| JPWO2021071802A5 (enExample) | ||
| JPWO2020033488A5 (enExample) |